MarketCap
Facebook
X
Telegram
SeaSpine Holdings Corporation Cost of Revenue | SPNE
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue SeaSpine Holdings Corporation
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 76.9 M | 56.8 M | 58 M | 56 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 76.9 M | 56 M | 61.9 M |
Quarterly Cost of Revenue SeaSpine Holdings Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 26.6 M | 19.1 M | 20.4 M | - | 18.3 M | 17.5 M | 15.4 M | - | 14.1 M | 11.7 M | 13.8 M | - | 14.4 M | 14.3 M | 13.6 M | - | 14.2 M | 14.6 M | 12.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 26.6 M | 11.7 M | 16 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Vapotherm
VAPO
|
40.4 M | - | 6.72 % | $ 34 M |  USA |
 |
Nevro Corp.
NVRO
|
139 M | - | - | $ 217 M | USA |
 |
Abiomed
ABMD
|
188 M | - | - | $ 17.2 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Venus Concept
VERO
|
20.5 M | - | - | $ 726 K | USA |
 |
Zynex
ZYXI
|
39.4 M | - | - | $ 21.1 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | - | - | $ 162 M |  France |
 |
Avanos Medical
AVNS
|
347 M | $ 24.99 | - | $ 1.16 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
2.17 M | - | -0.57 % | $ 7.12 M | USA |
 |
NanoVibronix
NAOV
|
2.4 M | - | - | $ 1.08 M | USA |
 |
Ra Medical Systems
RMED
|
63 K | - | 10.0 % | $ 610 K | USA |
 |
ReWalk Robotics Ltd.
RWLK
|
13.6 M | - | 7.07 % | $ 66.1 M |  Israel |
 |
STRATA Skin Sciences
SSKN
|
12.8 M | - | - | $ 6.6 M | USA |
 |
Abbott Laboratories
ABT
|
19.3 B | $ 100.1 | 2.67 % | $ 174 B | USA |
 |
Aethlon Medical
AEMD
|
2.79 M | $ 6.53 | 1.16 % | $ 4.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 5.74 | 2.5 % | $ 776 M | USA |
 |
Align Technology
ALGN
|
1.32 B | $ 140.65 | 0.1 % | $ 10.2 B | USA |
 |
Apyx Medical Corporation
APYX
|
19.8 M | $ 2.6 | 1.96 % | $ 107 M | USA |
 |
Accuray Incorporated
ARAY
|
290 M | $ 0.3 | 7.37 % | $ 36.8 M | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 10.72 | 6.88 % | $ 1.61 B | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 37.22 | 0.21 % | $ 1.71 B | USA |
 |
Butterfly Network
BFLY
|
51.9 M | $ 9.38 | 4.8 % | $ 2.32 B | USA |
 |
Bio-Rad Laboratories
BIO
|
1.24 B | $ 379.82 | 2.89 % | $ 10.4 B | USA |
 |
Bruker Corporation
BRKR
|
1.86 B | $ 63.86 | 0.98 % | $ 9.69 B | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 42.4 | 0.31 % | $ 62.8 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
110 M | $ 8.77 | 0.34 % | $ 639 M | Israel |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 11.52 | 5.74 % | $ 326 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 47.33 | 2.25 % | $ 1.47 B | USA |